ABL1 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain ABL1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 1 is closed. Of the trials that contain AFF1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [3].

BCR is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain BCR status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [3].

CBL is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains CBL status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

CSF3R is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains CSF3R status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 2 are closed. Of the trials that contain DEK status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 2 are phase 2 (0 open) [3].

ELL is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain ELL status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 2 are closed. Of the trials that contain FLT3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 4 are phase 2 (2 open) [3].

GATA1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains GATA1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

GATA2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains GATA2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 2 are phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 1 is closed. Of the trials that contain KIT status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (2 open) [3].

KMT2A is an inclusion eligibility criterion in 5 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 3 are open and 2 are closed. Of the trials that contain KMT2A status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (2 open) [3].

KRAS is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 5 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 3 are closed. Of the trials that contain MECOM status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain MLF1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 2 are phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain MLLT1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain MLLT10 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain MLLT3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain MLLT4 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

MPL is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains MPL status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains MYD88 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains NOTCH1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 2 are closed. Of the trials that contain NPM1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 4 are phase 2 (2 open) [3].

NRAS is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain NRIP3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 2 are closed. Of the trials that contain NUP214 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 2 are phase 2 (0 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 5 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 3 are closed. Of the trials that contain RPN1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain RUNX1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [3].

SF3B1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

SRSF2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

STAT3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains STAT3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [3].

U2AF1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains U2AF1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].

ZRSR2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains ZRSR2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [3].